Changchun GeneScience Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1948-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://english.ciac.cas.cn/
Clinical Trials
81
Active:3
Completed:27
Trial Phases
5 Phases
Phase 1:29
Phase 2:15
Phase 3:18
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (76 trials with phase data)• Click on a phase to view related trials
Phase 1
29 (38.2%)Phase 3
18 (23.7%)Phase 2
15 (19.7%)Phase 4
8 (10.5%)Not Applicable
6 (7.9%)Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
Not Applicable
Not yet recruiting
- Conditions
- EfficacySafetyMegestrol AcetateAdult Subject
- Interventions
- Drug: Low dose of Megestrol Acetate Oral Suspension combined with standard therapyDrug: Medium dose of Megestrol Acetate Oral Suspension combined with standard therapyDrug: High dose of Megestrol Acetate Oral Suspension combined with standard therapyDrug: Megestrol Acetate Oral Suspension Placebo combined with standard therapy
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 132
- Registration Number
- NCT07130617
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets
Not Applicable
Not yet recruiting
- Conditions
- Hyperprolactinemia
- Interventions
- Drug: Cabergoline tabletsDrug: Bromocriptine mesylate tablets
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 382
- Registration Number
- NCT07124221
- Locations
- 🇨🇳
Peking Union Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT07040930
- Locations
- 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Clinical Study of GenSci134 in Healthy Male Adults
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Drug: GenSci134Drug: GenSci134 PlaceboDrug: Recombinant Human Growth Hormone Injection (Norditropin®)
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT07016802
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Real-World Clinical Study for Malignant Tumor-Induced Cachexia
Withdrawn
- Conditions
- Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaMulticenter Observational Study
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6000
- Registration Number
- NCT07008248
- Locations
- 🇨🇳
Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 17
- Next
News
No news found